Skip navigation
Skip navigation

Regorafenib-induced hyperammonemic encephalopathy

Kuo, James C; Parakh, Sagun; Yip, Desmond


What is known and objective Regorafenib improves progression-free survival as a late-line treatment for patients with metastatic gastrointestinal stromal tumour (GIST). As a multitargeted tyrosine kinase inhibitor (TKI), the expected adverse events of regorafenib are similar to those reported with imatinib, sunitinib or sorafenib. We report the first case of hyperammonemic encephalopathy related to regorafenib in a patient with metastatic GIST. Case summary A 61-year-old man maintained on...[Show more]

CollectionsANU Research Publications
Date published: 2014
Type: Journal article
Source: Journal of Clinical Pharmacy and Therapeutics
DOI: 10.1111/jcpt.12160


File Description SizeFormat Image
01_Kuo_Regorafenib-induced_2014.pdf480.18 kBAdobe PDF    Request a copy

Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  27 November 2018/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator